Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + daunorubicin + cytarabine for newly diagnosed fit AML
ChiCTR2600128940Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by West China Hospital of Sichuan University. Primary endpoints: The percentage of blasts detected by flow cytometric immunophenotyping, The percentage of myeloblasts assessed by bone marrow morphological examination and 3 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600128940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128940.